20430 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring heteroatoms, e.g. piperazine; Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
#2CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV
#3COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF
#4CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF
#5Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance
#6ENGAGING THE CERVICAL SPINAL CORD CIRCUITRY TO RE-ENABLE VOLITIONAL CONTROL OF HAND FUNCTION IN TETRAPLEGIC SUBJECTS
#7USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANC
#8INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE
#9CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV
#101,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF
#11SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
#12NON-AROMATIC CYCLIC-PYRIMIDINE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
#13DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF
#14Small Molecule IL-17A Modulators
#151,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF
#16URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
#17SPIROCYCLIC COMPOUND AS KRAS-G12C INHIBITOR
#18SPIROHETEROCYCLE DERIVATIVE HAVING SEROTONIN RECEPTOR BINDING ACTIVITY
#19SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
#20ENGAGING THE CERVICAL SPINAL CORD CIRCUITRY TO RE-ENABLE VOLITIONAL CONTROL OF HAND FUNCTION IN TETRAPLEGIC SUBJECTS
#21MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV
#22SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
#23PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE
#24CDK INHIBITORS
#25HIGH-ACTIVITY WNT PATHWAY INHIBITOR COMPOUND
#26TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY
#27HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION
#28FUSED HETEROAROMATIC PYRROLIDINONES
#29HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
#30ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS
#31GALACTOKINASE INHIBITORS
#32TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS
#33SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
#34SHP2 INHIBITORS AND USES THEREOF
#35FUSED HETEROAROMATIC PYRROLIDINONES
#36METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL
#37INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4
#38MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV
#39CDK INHIBITORS
#40Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
#41Transient protection of normal cells during chemotherapy
#42THERAPEUTIC REGIMENS FOR TREATMENT OF CANCER USING ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS
#43HSPC-sparing treatments for RB-positive abnormal cellular proliferation
#44Indole derivatives and their use as protein kinase inhibitors
#45TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION
#46Uses
#47HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
#48Transient protection of normal cells during chemotherapy
#49CDK inhibitors
#50N3-substituted iminopyrimidinones as antimalarial agents
#51Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
#52Modulators of toll-like receptors
#53Uses
#54USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS
#55Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
#56TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION
#57Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors
#58K-RAS MUTATIONS AND ANTAGONISTS
#59Treatment of addiction and impulse-control disorders using PDE7 inhibitors
#60Highly active anti-neoplastic and anti-proliferative agents
#61Indole derivatives and their use as protein kinase inhibitors
#62HSPC-sparing treatments for RB-positive abnormal cellular proliferation
#63Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders
#64HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
#65Transient protection of normal cells during chemotherapy
#66TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION
#67Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
#68NORADRENERGIC DRUG TREATMENT OF OBSTRUCTIVE SLEEP APNEA
#69Transient protection of normal cells during chemotherapy
#70Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
#71FUSED HETEROAROMATIC PYRROLIDINONES
#72Modulators of toll-like receptors
#73Methods and compositions for treating bacterial infection
#74HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
#75Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
#76Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors
#77Uses
#78Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
#79HSPC-sparing treatments for RB-positive abnormal cellular proliferation
#80Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
#81Transient protection of normal cells during chemotherapy
#82MODULATORS OF TOLL-LIKE RECEPTORS
#83Methods and compositions for treating bacterial infection
#84Transient protection of normal cells during chemotherapy
#85GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS
#86Highly Active Anti-Neoplastic and Anti-Proliferative Agents
#87Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
#88Substituted imidazo[1,2-b]pyrazoles as bruton'S tyrosine kinase modulators
#89Method of treating a CNS injury with a PDE1 inhibitor
#90USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS
#91Modulators of toll-like receptors
#92Modulators of toll-like receptors for the treatment of HIV
#93Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4
#94FUSED HETEROAROMATIC PYRROLIDINONES
#95Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
#96Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
#97Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
#98Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
#99Substituted heteroaryl compounds and methods of use
#100Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
#101Substituted heteroaryl compounds and methods of use
#102Substituted heteroaryl compounds and methods of use
#103Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
#104Tetrahydroquinazolinone derivatives as PARP inhibitors
#105Substituted annellated pyrimidines and use thereof
#106COMBINATION OF KINASE INHIBITORS AND USES THEREOF
#1074,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis B
#108Hetero-bicyclic derivatives as HCV inhibitors
#109Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
#110Transient protection of normal cells during chemotherapy
#111Transient protection of normal cells during chemotherapy
#112Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
#113HSPC-sparing treatments for RB-positive abnormal cellular proliferation
#114Use of PDE7 inhibitors for the treatment of movement disorders
#1151,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
#116Treatment of addiction and impulse-control disorders using PDE7 inhibitors
#117Fused heteroaromatic pyrrolidinones
#118Fused heteroaromatic pyrrolidinones as SYK inhibitors
#119Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
#120Fused heteroaromatic pyrrolidinones
#121USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS
#122SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
#123Modulators of Muscarinic Receptors
#124Modulators of toll-like receptors
#125Lyophilization formulation
#126Use of PDE7 inhibitors for the treatment of movement disorders
#127Remedy for sleep disturbance
#128USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN
#129USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS
#130Modulators of muscarinic receptors
#131Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-]pyrimidin-6-one derivatives
#132Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-]pyrimidin-6-one derivatives
#133Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient
#134Remedy for sleep disturbance